Iron oxide nanoparticle m-PEG-silane - Industrial Technology Research Institute

Drug Profile

Iron oxide nanoparticle m-PEG-silane - Industrial Technology Research Institute

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Industrial Technology Research Institute
  • Class Contrast media; Ferric compounds; Oxides
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver cancer

Most Recent Events

  • 06 Apr 2018 MegaPro Biomedical plans a phase II trial for Iron deficiency anaemia, in May 2018 (NCT03485053)
  • 23 Jan 2018 MegaPro Biomedical plans a phase II trial for Liver cancer (Diagnosis) in March 2018 (NCT03407495)
  • 15 Jan 2018 MegaPro Biomedical plans a phase Ib trial in Healthy volunteers (Diagnosis) in Taiwan (IV, Injection) (NCT03399214)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top